Dr. Jennifer Chuy, MD
Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $11,968 | 4 | 79.8% |
| Food and Beverage | $1,561 | 70 | 10.4% |
| Consulting Fee | $1,250 | 1 | 8.3% |
| Education | $219.71 | 3 | 1.5% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $13,316 | 5 | $0 (2019) |
| Amgen Inc. | $366.05 | 13 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $235.22 | 6 | $0 (2019) |
| AbbVie, Inc. | $113.03 | 5 | $0 (2018) |
| Takeda Pharmaceuticals U.S.A., Inc. | $110.84 | 3 | $0 (2018) |
| Ipsen Biopharmaceuticals, Inc | $101.44 | 3 | $0 (2018) |
| Astellas Pharma US Inc | $99.95 | 1 | $0 (2024) |
| Genentech USA, Inc. | $93.38 | 5 | $0 (2018) |
| Daiichi Sankyo Inc. | $85.60 | 5 | $0 (2018) |
| Taiho Oncology, Inc. | $68.59 | 5 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $116.20 | 2 | Astellas Pharma US Inc ($99.95) |
| 2023 | $42.93 | 2 | Seagen Inc. ($23.12) |
| 2019 | $2,330 | 2 | Celgene Corporation ($2,310) |
| 2018 | $5,876 | 46 | Celgene Corporation ($4,767) |
| 2017 | $6,633 | 26 | Celgene Corporation ($6,240) |
All Payment Transactions
78 individual payment records from CMS Open Payments — Page 3 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/25/2018 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $11.53 | General |
| Category: Oncology | ||||||
| 01/10/2018 | Celgene Corporation | Abraxane (Drug) | — | Cash or cash equivalent | $4,766.50 | Research |
| Study: ABI-007-PANC-007 - nab1-paclitaxel (Abraxane) plus gemcitabine in subjects with locally advanced pancreatic cancer (LAPC): An international, open-label, multi-center, Phase 2 study (LAPACT). • Category: Oncology | ||||||
| 12/07/2017 | Spectrum Pharmaceuticals Inc. | Folotyn (Drug) | Food and Beverage | In-kind items and services | $12.53 | General |
| Category: Not Applicable | ||||||
| 12/05/2017 | Lilly USA, LLC | ERBITUX (Drug), CYRAMZA | Food and Beverage | In-kind items and services | $17.67 | General |
| Category: Oncology | ||||||
| 12/01/2017 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Food and Beverage | In-kind items and services | $14.57 | General |
| Category: ONCOLOGY | ||||||
| 11/10/2017 | GENZYME CORPORATION | JEVTANA (Drug) | Food and Beverage | In-kind items and services | $12.49 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2017 | Novartis Pharmaceuticals Corporation | JADENU (Drug), PROMACTA | Food and Beverage | In-kind items and services | $24.18 | General |
| Category: HEMATOLOGY | ||||||
| 10/24/2017 | Genentech USA, Inc. | Avastin (Biological) | Food and Beverage | In-kind items and services | $17.18 | General |
| Category: BioOncology | ||||||
| 10/20/2017 | Amgen Inc. | Kyprolis (Biological) | Food and Beverage | In-kind items and services | $18.14 | General |
| Category: Oncology | ||||||
| 10/18/2017 | Celgene Corporation | Abraxane (Drug) | Consulting Fee | Cash or cash equivalent | $1,250.00 | General |
| Category: Oncology | ||||||
| 10/05/2017 | Celgene Corporation | Abraxane (Drug) | Food and Beverage | In-kind items and services | $122.43 | General |
| Category: Oncology | ||||||
| 09/21/2017 | Ferring Pharmaceuticals Inc. | FIRMAGON (Drug) | Food and Beverage | In-kind items and services | $15.87 | General |
| Category: UROLOGY | ||||||
| 09/20/2017 | Amgen Inc. | Aranesp (Biological), Nplate, Prolia | Food and Beverage | In-kind items and services | $13.88 | General |
| Category: Nephrology | ||||||
| 08/27/2017 | AbbVie, Inc. | Creon (Drug) | Food and Beverage | In-kind items and services | $23.68 | General |
| Category: Endocrinology | ||||||
| 08/24/2017 | PFIZER INC. | SUTENT (Drug), XALKORI, INLYTA | Food and Beverage | In-kind items and services | $15.90 | General |
| Category: ONCOLOGY;RESPIRATORY | ||||||
| 07/20/2017 | AbbVie, Inc. | Venclexta (Drug) | — | In-kind items and services | $23.89 | Research |
| Category: Virology | ||||||
| 07/12/2017 | Novartis Pharmaceuticals Corporation | JADENU (Drug), PROMACTA | Food and Beverage | In-kind items and services | $24.88 | General |
| Category: HEMATOLOGY | ||||||
| 06/13/2017 | Genentech USA, Inc. | Avastin (Biological), Tarceva, Alecensa | Food and Beverage | In-kind items and services | $17.05 | General |
| Category: BioOncology | ||||||
| 06/08/2017 | Millennium Pharmaceuticals, Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $12.72 | General |
| Category: Oncology | ||||||
| 05/30/2017 | Taiho Oncology, Inc. | Lonsurf (Drug) | Food and Beverage | Cash or cash equivalent | $13.77 | General |
| Category: Oncology | ||||||
| 05/16/2017 | Genentech USA, Inc. | Avastin (Biological) | Food and Beverage | In-kind items and services | $16.81 | General |
| Category: BioOncology | ||||||
| 05/05/2017 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $11.84 | General |
| Category: ONCOLOGY | ||||||
| 05/02/2017 | Celgene Corporation | Abraxane (Drug) | — | Cash or cash equivalent | $4,867.25 | Research |
| Study: ABI-007-PANC-007 • Category: Oncology | ||||||
| 04/25/2017 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $13.77 | General |
| Category: Anemia | ||||||
| 04/19/2017 | Eisai Inc. | Halaven (Drug) | Food and Beverage | Cash or cash equivalent | $16.93 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ABI-007-PANC-007 | Celgene Corporation | $4,867 | 1 |
| ABI-007-PANC-007 - nab1-paclitaxel (Abraxane) plus gemcitabine in subjects with locally advanced pancreatic cancer (LAPC): An international, open-label, multi-center, Phase 2 study (LAPACT). | Celgene Corporation | $4,767 | 1 |
| nab1-paclitaxel (Abraxane) plus gemcitabine in subjects with locally advanced pancreatic cancer (LAPC): An international, open-label, multi-center, Phase 2 study (LAPACT). (ABI-007-PANC-007) | Celgene Corporation | $2,310 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 143 | 438 | $251,114 | $38,579 |
| 2022 | 4 | 116 | 277 | $166,415 | $26,756 |
| 2021 | 7 | 202 | 567 | $327,080 | $60,214 |
| 2020 | 8 | 264 | 542 | $218,524 | $44,759 |
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 2 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 13 | 16 | $4,900 | $511.55 | 10.4% |
About Dr. Jennifer Chuy, MD
Dr. Jennifer Chuy, MD is a Student in an Organized Health Care Education/Training Program healthcare provider based in Bronx, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/07/2010. The National Provider Identifier (NPI) number assigned to this provider is 1174826531.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jennifer Chuy, MD has received a total of $14,999 in payments from pharmaceutical and medical device companies, with $116.20 received in 2024. These payments were reported across 78 transactions from 25 companies. The most common payment nature is "" ($11,968).
As a Medicare-enrolled provider, Chuy has provided services to 725 Medicare beneficiaries, totaling 1,824 services with total Medicare billing of $170,308. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Practice Information
- Specialty Student in an Organized Health Care Education/Training Program
- Other Specialties Hematology & Oncology
- Location Bronx, NY
- Active Since 12/07/2010
- Last Updated 06/02/2017
- Taxonomy Code 390200000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1174826531
Products in Payments
- Abraxane (Drug) $13,316
- NINLARO (Drug) $123.56
- SANDOSTATIN LAR (Drug) $120.80
- XGEVA (Biological) $103.26
- JADENU (Drug) $94.24
- Avastin (Biological) $93.38
- Neulasta (Biological) $93.18
- INJECTAFER (Drug) $85.60
- Lonsurf (Drug) $68.59
- Creon (Drug) $66.17
- OPDIVO (Biological) $58.52
- Venclexta (Drug) $46.86
- Kyprolis (Biological) $35.78
- Lenvima (Drug) $34.01
- Aranesp (Biological) $33.88
- FIRMAGON (Drug) $31.96
- KEYTRUDA (Biological) $31.65
- Folotyn (Drug) $27.79
- XALKORI (Drug) $25.75
- JEVTANA (Drug) $24.31
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Student in an Organized Health Care Education/Training Program Doctors in Bronx
Dr. David Altschul, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $394,687
Edvard Skripochnik, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $127,559
Dr. Cynthia Armand
Student in an Organized Health Care Education/Training Program — Payments: $68,024
Dr. Eric Woods, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $40,336
Ms. Kavita Gupta, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $31,772
Dr. Dmitriy Nevelev, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $30,107